N
BIOR

Nuveen’s Biora Therapeutics, Inc. Common Stock BIOR Stock Holding History

Nuveen’s Portfolio BIOR Stock Details BIOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-55
Closed -$65K – 3601
2021
Q1 		$65K Sell
55
-6
-10% -$8.27K ﹤0.01% 3296
2020
Q4 		$81K Buy
+61
New +$89.5K ﹤0.01% 3243

Other funds holding BIOR

ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
PGM
Parian Global Management Pound Ridge, New York $30.8M AUM 51.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nuveen's BIOR Position: Q2 2021 in Review

Nuveen sold out of Biora Therapeutics, Inc. Common Stock (BIOR) in Q2 2021, closing a stake of 55 shares — an estimated $65K sold.

Nuveen first reported a position in BIOR in Q4 2020 and held it in 2 quarters. The position peaked at $81K in Q4 2020. 42 funds tracked by Wall St. Rank hold BIOR as of Q2 2021.

  • Nuveen reported no remaining Biora Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Nuveen sold 55 Biora Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $65K.
  • Nuveen first reported a position in Biora Therapeutics, Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • Nuveen's Biora Therapeutics, Inc. Common Stock position peaked at $81K in Q4 2020.
  • 42 funds tracked by Wall St. Rank held Biora Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Nuveen's 13F filing for Q2 2021, filed 16 Aug 2021.